Table 3.

Patient follow-up and clinical measures in studying BNT162b2 vaccine on long COVID risks in children and adolescents. PASC: post-acute sequelae of SARS-CoV-2 infection.

	Vaccinated	Unvaccinated	Overall
Delta study in adolescents
Follow-up
Total follow-up — no. of person-wk	1,521,152	397,762	1,918,914
Median [Q1, Q3]	17 [15, 19]	17 [15, 19]	17 [15, 19]
Incidence rate per 10,000 person-wk
Documented infection	1.97	53.10	12.56
Conclusive or probable PASC	0.11	3.54	0.82
Respiratory cluster	0.01	0.63	0.14
Musculoskeletal cluster	0.03	0.68	0.17
Cardiac cluster	0.01	0.70	0.16
Syndromic cluster	0.03	1.26	0.29
Gastrointestinal cluster	0.02	0.38	0.09
Omicron study in children
Follow-up
Total follow-up — no. of person-wk	4,120,783	3,265,395	7,386,178
Median [Q1, Q3]	44 [39, 46]	40 [31, 45]	42 [35, 46]
Incidence rate per 10,000 person-wk
Documented infection	4.56	16.43	9.81
Conclusive or probable PASC	0.33	1.07	0.66
Respiratory cluster	0.15	0.41	0.27
Musculoskeletal cluster	0.04	0.15	0.09
Cardiac cluster	0.05	0.14	0.09
Syndromic cluster	0.08	0.23	0.15
Gastrointestinal cluster	0.06	0.15	0.10
Omicron study in adolescents
Follow-up
Total follow-up — no. of person-wk	1,491,914	1,747,295	3,239,209
Median [Q1, Q3]	43 [36, 46]	40 [31, 45]	41 [33, 45]
Incidence rate per 10,000 person-wk
Documented infection	3.91	21.19	13.23
Conclusive or probable PASC	0.24	1.43	0.88
Respiratory cluster	0.03	0.29	0.17
Musculoskeletal cluster	0.05	0.27	0.17
Cardiac cluster	0.07	0.23	0.16
Syndromic cluster	0.08	0.43	0.27
Gastrointestinal cluster	0.01	0.16	0.09